Lod

BIRD - Israel-U.S. Binational Industrial R&D Foundation to invest $9.6 million in 10 new projects: The approved projects, with an overall budget of $24.5 million, involve innovations in the areas of Agrotech, Biotechnology, Electronics, Energy, Foodtech,

Retrieved on: 
星期三, 一月 31, 2024
Misgav, MD, BIRD Foundation, Commerce, BIRD, Planner, Associate, Partnership, Yokneam Illit, Mayo Clinic, History, TEL, Carbon, Splenic infarction, Lod, Intelligence, Sheba Medical Center, Patient, Ministry, Mondelez International, NIST, Approval, Virtual reality, Anopheles, Agriculture, Anopheles stephensi, Parity, Rehovot, ATCC, Hope, Malaria, Pharmaceutical industry

In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.

Key Points: 
  • In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.
  • The BIRD Foundation promotes collaborations between U.S. and Israeli companies in various technological sectors for joint product development.
  • In addition to providing conditional grants of up to $1.5 million, the Foundation assists by working with companies to identify potential strategic partners and facilitate introductions.
  • The ten projects approved by the Board of Governors are in addition to the over 1000 projects that the BIRD Foundation has approved for funding during its 46-year history.

Leumi concludes Q3 2023 with an approximate NIS 1.8 billion ($463 million) profit

Retrieved on: 
星期三, 十一月 29, 2023
Corporation, NPL, War, Bank, Organization, Bank statement, IDF, Uncertainty, Farmer, Rehabilitation, Share repurchase, Growth, Common equity, HQ, TEL, TASE, Holding company, Tutoring, Cryptocurrency, Bank Leumi, Lod

Net income in the first nine months of 2023 amounted to NIS 5.2 billion ($1.36 billion), compared to NIS 5.38 billion ($1.41 billion) in the corresponding period last year.

Key Points: 
  • Net income in the first nine months of 2023 amounted to NIS 5.2 billion ($1.36 billion), compared to NIS 5.38 billion ($1.41 billion) in the corresponding period last year.
  • Housing loans as at September 30, 2023 totaled NIS 129.6 billion ($33.9 billion), compared to NIS 120.9 billion ($31.6 billion) as at December 31, 2022 - a 7.2% increase.
  • Middle-market credit as at September 30, 2023 totaled NIS 64.4 billion ($16.8 billion), compared to NIS 60.8 billion ($15.9 billion) as at December 31, 2022 - a 5.9% increase.
  • Deposits by small businesses as at September 30, 2023 totaled NIS 53.2 billion ($13.9 billion), compared to NIS 55.4 billion ($14.5 billion) as at December 31, 2022 - a 4.0% decrease.

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

Retrieved on: 
星期一, 十月 23, 2023
URL, Mindray, N-terminal prohormone of brain natriuretic peptide, Myocardial injury after non-cardiac surgery, Biomarker, Antigen, Acute coronary syndrome, HyTest Ltd, Research, Antibody, ACS, CVD, AACC, CV, Lod, 99th Infantry Division (United States), Diagnosis, Death, Heart failure, SZSE, Medical device

The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.

Key Points: 
  • The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.
  • While CVDs are the leading cause of death worldwide, early detection is key in saving lives.
  • The two assays are the collaborative effort of Mindray and HyTest, a Mindray company and a prominent global provider of antibodies and antigens.
  • HyTest, renowned for its cardiac biomarker expertise, had its cardiac troponin complex material selected as the international troponin standard by AACC in 2004.

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

Retrieved on: 
星期一, 十月 23, 2023
URL, Mindray, N-terminal prohormone of brain natriuretic peptide, Myocardial injury after non-cardiac surgery, Biomarker, Antigen, Acute coronary syndrome, HyTest Ltd, Research, Antibody, ACS, CVD, AACC, CV, Lod, 99th Infantry Division (United States), Diagnosis, Death, Heart failure, SZSE, Medical device

The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.

Key Points: 
  • The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.
  • While CVDs are the leading cause of death worldwide, early detection is key in saving lives.
  • The two assays are the collaborative effort of Mindray and HyTest, a Mindray company and a prominent global provider of antibodies and antigens.
  • HyTest, renowned for its cardiac biomarker expertise, had its cardiac troponin complex material selected as the international troponin standard by AACC in 2004.

Leumi concludes Q2 2023 with a NIS 2.4 billion ($649 million) profit - and with a dividend distribution and share buyback of some NIS 1 billion ($270 million)

Retrieved on: 
星期二, 八月 15, 2023
Bank statement, Common equity, Valley Bank, Share repurchase, TEL, HQ, TASE, Growth, NIS, Bank, Holding company, Bank Leumi, Lod

Return on equity in the second quarter of 2023 was 19.4%, compared to 18.5% in the corresponding quarter last year.

Key Points: 
  • Return on equity in the second quarter of 2023 was 19.4%, compared to 18.5% in the corresponding quarter last year.
  • Efficiency ratio in the second quarter of 2023 was 29.5%, compared with 35% in the corresponding quarter last year.
  • Dividend and share buyback: The Bank's Board of Directors approved a dividend distribution totaling NIS 736 million ($199 million), which together with a share buyback of NIS 300 million ($81 million) represent approx.
  • The share buyback which took place is part of an overall plan of up to NIS 800 million ($216 million).

Leumi Concludes Q1 2023 with Continued Growth - and with a Dividend Distribution and Share Buyback of over NIS 1 Billion ($277 Million)

Retrieved on: 
星期二, 五月 23, 2023
Bank statement, Common equity, National bank, Valley Bank, Share repurchase, TEL, HQ, TASE, Growth, NIS, Bank, Bank Leumi, Lod

Net of the one-off deduction with respect to the bank's shares in Valley, net income reached NIS 2.1 billion ($581 million).

Key Points: 
  • Net of the one-off deduction with respect to the bank's shares in Valley, net income reached NIS 2.1 billion ($581 million).
  • Leumi declares a share buyback of NIS 800 million ($221 million), in addition to a 30% quarterly dividend distribution.
  • Dividend: The Bank's Board of Directors approved a NIS 294 million ($81 million) dividend distribution, which constitutes 30% of the net income for Q1 2023.
  • Net interest income in the first quarter of 2023 totaled NIS 3.9 billion ($1.08 billion), compared to NIS 2.7 billion ($0.75 billion) in the corresponding quarter last year*.

Leumi Records Strong Results in 2022: Return on Equity of 19% in Q4 and 17% for Y2022

Retrieved on: 
星期二, 三月 14, 2023
Biophysical environment, NIS, ESG, Social, Work, HQ, Heart, Investment, Sale, TASE, Bank, Bank statement, Growth, IronSource, Common equity, CPI, Valley Bank, Lead, Cryptocurrency, Bank Leumi, Lod

Net income in Q4 reached NIS 2.3 billion ($654 million), compared to NIS 1.5 billion ($426 million) in the corresponding quarter last year.

Key Points: 
  • Net income in Q4 reached NIS 2.3 billion ($654 million), compared to NIS 1.5 billion ($426 million) in the corresponding quarter last year.
  • Return on equity in Q4 2022 was 19%, compared to 14% in the corresponding quarter last year.
  • Substantial improvement in the efficiency ratio: The efficiency ratio continued to improve in Q4 2022 - reaching 31.8%.
  • In the entire year, net of the results of Leumi USA, the efficiency ratio was 37.2%, compared to 45.8% in 2021.

Leumi Continues to Deliver Strong Results - Net Income in the First Nine Months of 2022 reaches NIS 5.4 Billion ($1.5 Billion)

Retrieved on: 
星期二, 十一月 29, 2022
Growth, NIS, HQ, Toyota Publica, Bank, Common equity, Sale, Shareholder, TASE, NPL, Valley Bank, Fossil fuel, Renewable energy, Airline, Lod, Q3, Bank Leumi, Credit

Net income in the first nine months of the year reached NIS 5.4 billion ($1.5 billion), compared to NIS 4.6 billion ($1.3 billion) in the corresponding period last year.

Key Points: 
  • Net income in the first nine months of the year reached NIS 5.4 billion ($1.5 billion), compared to NIS 4.6 billion ($1.3 billion) in the corresponding period last year.
  • > Finance incomein the first nine months of 2022, net of the results of Leumi USA, reached NIS 9.9 billion ($2.8 billion), compared to NIS 8.5 billion ($2.4 billion) in the corresponding period last year, a 16.5% increase.
  • > Shareholder's equityas at September 30, 2022 totaled NIS 48 billion ($14 billion), compared to NIS 41.8 billion ($12 billion) as at September 30, 2021.
  • > Deposits by the publicas at September 30, 2022 totaled NIS 546.7 billion ($154.3 billion), compared with NIS 478.8 billion ($135.1 billion) as at September 30, 2021 - a 14.2% increase.

Multi-omics Startup Pleno Inc. Announces $40 Million in Series A Funding Led by Deerfield Management with Participation by Foresite Capital

Retrieved on: 
星期三, 十月 12, 2022
Biotechnology, Health, Technology, Clinical Trials, Telecommunications, Quality of life, Proteomics, Lod, Disease, Telecommunication, NIPT, Patient, Drug development, Mesa, RNA, Technology, Infection, Genotyping, MD, Industry, En Pleno Vuelo, Healthcare disparity in Massachusetts, Foresite Capital, Methylation, DNA, Limiting factor, Biomedical Research, Inc., Pharmaceutical industry, Mobile phone, Medical imaging

Pleno Inc., a multi-omic instrument platform company revolutionizing biological target detection for clinical testing and biomedical research, announced the close of $40 million in Series A financing led by Deerfield Management Company with participation by Foresite Capital .

Key Points: 
  • Pleno Inc., a multi-omic instrument platform company revolutionizing biological target detection for clinical testing and biomedical research, announced the close of $40 million in Series A financing led by Deerfield Management Company with participation by Foresite Capital .
  • Deerfield is proud to lead Plenos Series A financing, said Andrew ElBardissi, MD, Partner at Deerfield Management.
  • "Genotyping and sequencing have enhanced our understanding of the molecular drivers of disease and its response to treatment, particularly in oncology.
  • Yet the cost and increasing complexity of these centralized measurements causes healthcare disparities," said Dr. Vik Bajaj, Managing Director at Foresite Capital.

PARTNER COMMUNICATIONS ANNOUNCES RECEIVING A LAWSUIT

Retrieved on: 
星期三, 八月 17, 2022
Tel Aviv Stock Exchange, ADSS, Lawsuit, MRT, Telecommunication, Partner, Probability, Court, Article, Company, Lod, Articles of association, NASDAQ, Nasdaq, Partner Communications Company, TASE, Internet, Plaintiff, Holding company, Association

ROSH HA'AYIN, Israel, Aug. 17, 2022 /PRNewswire/ --Partner Communications Company Ltd. ("Partner" or "the Company") (NASDAQ: PTNR) (TASE: PTNR), a leading Israeli communications operator,reports that on August 17, 2022, the Company received a lawsuit filed by Lapidot Capital Ltd. (the "Plaintiff"), that hold 2,173,126 of the Company's shares (the "Plaintiff's Shares"), in the Central District Court in Lod (the "Lawsuit").

Key Points: 
  • ROSH HA'AYIN, Israel, Aug. 17, 2022 /PRNewswire/ --Partner Communications Company Ltd. ("Partner" or "the Company") (NASDAQ: PTNR) (TASE: PTNR), a leading Israeli communications operator,reports that on August 17, 2022, the Company received a lawsuit filed by Lapidot Capital Ltd. (the "Plaintiff"), that hold 2,173,126 of the Company's shares (the "Plaintiff's Shares"), in the Central District Court in Lod (the "Lawsuit").
  • The Plaintiff's Shares are currently registered under the Plaintiff's name in the Company's shareholder registry as Founding Israeli Shareholder shares, as defined in the Company's Articles of Association.
  • Due to the preliminary stage of the proceeding, the Company is unable to evaluate the probability of success of the Lawsuit.
  • Partner Communications Company Ltd. is a leading Israeli provider of telecommunications services (cellular, fixed-line telephony, internet and television services).